Seeking Alpha
Profile| Send Message|
( followers)  

Next week is a busy earnings season, with many quarterly earnings releases scheduled and a bunch of stocks to watch. However, my focus is on biotechnology and drugs stocks that have earnings due in the next week. This article provides earnings previews on several stocks to consider in anticipation of their earnings reports. Use this list as a potential starting point for your analysis.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): May 7, 2012

BioCryst is a biotechnology company that designs, optimizes and develops drugs that block enzymes involved in therapeutic areas of interest to the company.

BioCryst Pharmaceuticals has a market cap of $189.33 million and will report its first-quarter earnings results on May 7, 2012, before market open. First-quarter revenue is expected to be $5.90 million compared with $5.44 million for the same quarter last year. Earnings per share for the first quarter are expected to be loss of 26 cents from loss of 29 cents in the year-ago period. BioCryst Pharmaceuticals is currently trading around $3.83 with a 52-week range of $2.28 to $5.95.

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP): May 7, 2012

Salix Pharmaceuticals is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal diseases, which are those affecting the digestive tract.

Salix Pharmaceuticals has a market cap of $3.00 billion and will report its first-quarter earnings results on May 7, 2012, after market close. First-quarter revenue is expected to be $168.27 million compared with $105.90 million for the same quarter last year. Earnings per share for the first quarter are expected to be 57 cents from 34 cents in the year-ago period. Salix Pharmaceuticals is currently trading around $50.55 with a 52-week range of $25.64 to $53.99.

Dendreon Corporation (NASDAQ:DNDN): May 7, 2012

Dendreon is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. Dendreon's product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers.

Dendreon has a market cap of $1.75 billion and will report its first-quarter earnings results on May 7, 2012, after market close. First-quarter revenue is expected to be $81.23 million compared with $28.06 million for the same quarter last year. Earnings per share for the first quarter are expected to be loss of 63 cents from loss of 77 cents in the year-ago period. Dendreon is currently trading around $11.35 with a 52-week range of $6.46 to $43.96.

Par Pharmaceutical Companies, Inc. (NYSE:PRX): May 8, 2012

Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States.

Par Pharmaceutical Companies has a market cap of $1.54 billion and will report its first-quarter earnings results on May 8, 2012, before market open. First-quarter revenue is expected to be $237.84 million compared with $232.95 million for the same quarter last year. Earnings per share for the first quarter are expected to be 73 cents from 96 cents in the year-ago period. Par Pharmaceutical Companies is currently trading around $42.03 with a 52-week range of $24.85 to $42.25.

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS): May 8, 2012

Isis Pharmaceuticals, Inc. is engaged in antisense technology, exploiting a drug discovery platform to create a pipeline of drugs. It operates in the Drug Discovery and Development operations segments.

Isis Pharmaceuticals has a market cap of $822.3 million and will report its first-quarter earnings results on May 8, 2012, after market close. First-quarter revenue is expected to be $22.72 million compared with $21.15 million for the same quarter last year. Earnings per share for the first quarter are expected to be loss of 26 cents from loss of 20 cents in the year-ago period. Isis Pharmaceuticals is currently trading around $8.21 with a 52-week range of $6.25 to $9.49.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA): May 9, 2012

Teva is a global pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories.

Teva has a market cap of $42.98 billion and will report its first-quarter earnings results on May 9, 2012, before market open. First-quarter revenue is expected to be $5.51 billion compared with $4.08 billion for the same quarter last year. Earnings per share for the first quarter are expected to be $1.44 from $1.04 in the year-ago period. Teva is currently trading around $45.63 with a 52 week range of $35.00 to $51.15.

Savient Pharmaceuticals, Inc. (SVNT): May 9, 2012

Savient Pharmaceuticals is a specialty biopharmaceutical company focused on commercializing KRYSTEXXA (pegloticase) in the United States and completing the development and seeking regulatory approval outside of the United States for KRYSTEXXA, particularly in the European Union.

Savient Pharmaceuticals has a market cap of $173.04 million and will report its first-quarter earnings results on May 9, 2012, before market open. First-quarter revenue is expected to be $4.79 million compared with $1.29 million for the same quarter last year. Earnings per share for the first quarter are expected to be loss of 46 cents from loss of 19 cents in the year-ago period. Savient Pharmaceuticals is currently trading around $2.39 with a 52-week range of $1.82 to $11.91.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA): May 9, 2012

Ariad Pharmaceuticals is a biopharmaceutical company and the company's pipeline contains three product candidates: ponatinib, AP26113 and ridaforolimus.

Ariad Pharmaceuticals has a market cap of $2.670 billion and will report its first-quarter earnings results on May 9, 2012, before market open. First-quarter revenue is expected to be $0.3 million compared with $0.056 million for the same quarter last year. Earnings per share for the first quarter are expected to be loss of 26 cents from loss of 29 cents in the year-ago period. Ariad Pharmaceuticals is currently trading around $16.80 with a 52-week range of $7.55 to $16.96.

Sources: Some of the data is sourced from Google Finance, Yahoo Finance and investors site.

Disclaimer: I am not a registered investment advisor and do not provide specific investment advice. The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. It is up to the investors to make the correct decision after necessary research.

Source: Biotechnology And Drugs Stocks To Watch Next Week